AM2019 PAN15 Gynecological Oncology in the Era of Precision Medicine
This panel session will bring together four experts who can present recent advances in gynecological oncology research and how it can guide our current practice. Cervical and endometrial cancers have a varied response to treatment and there have been several recent discoveries in how molecular and imaging markers can help risk-
stratify patients. Topics in this session will include 1) novel imaging markers of prognosis and treatment response, 2) recent advances in the surgical approach to cervical cancer, 3) molecular markers of prognosis and use in clinical decision making, and 4) novel targeted therapies in gynecological cancers.
The meeting is designed to meet the interests of radiation oncologists, medical oncologists, surgeons, radiation biologists, and residents.
- Identify how imaging can help predict prognosis and response to treatment for cervical cancers.
- Describe a molecular marker of prognosis and how it can help guide treatment decisions.
- Explore how immunotherapy and radiotherapy have been combined in the treatment of cervical cancer.
The following persons served as faculty for this activity:
Jocelyn Chapman, MD is employed at UCSF Helen Diller Family Comprehensive Cancer Center and has no financial relationships to disclose.
Carien Creutzberg, MD, PhD is employed at Leiden University Medical Center and has no financial relationships to disclose.
Jyoti Mayadev, MD is employed at the University of California San Diego and consults for Varian Medical Systems and Astra Zeneca.
Julie Schwarz, MD, PhD is employed at Washington University School of Medicine and has no financial relationships to disclose.
Tracey Schefter, MD is employed at University of Colorado School of Medicine and has no financial relationships to disclose.
Tracy S. Sherertz, MD is employed at Kaiser Permanente Capitol Hill and has no financial relationships to disclose.
Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Live activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.